Search Results 501-510 of 17839 for Coagulation

1. A Study of BBI608 Combined with Standard Chemotherapies in Adult Patients who have Pancreatic Cancer - Mayo Clinic

   Acceptable coagulation studies as demonstrated by prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits (+/-15%); No clinically ...

2. A Study of Pembrolizumab (MK-3475) Versus Placebo in Combination with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer - Mayo Clinic

   AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN. Coagulation. INR or PT ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT/PTT ...

3. Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Patients with coagulation problems and active bleeding in the last month prior to cycle 1 day 1 (peptic ulcer, epistaxis, spontaneous bleeding); Previous ...

4. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation - Mayo Clinic

   ... coagulation. In the Phase 2 portion of the trial only, subjects who have previously received treatment with an inhibitor of Isocitrate dehydrogenase protein ...

5. A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy - Mayo Clinic

   Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening. Exclusion Criteria: Exhibits evidence of ...

6. Temozolomide and Irinotecan Hydrochloride with or without Bevacizumab in Treating Young Patients with Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors - Mayo Clinic

   Adequate coagulation defined as. International normalized ratio (INR)/prothrombin time (PT) ≤ 1.5 x upper limit of normal. Exclusion Criteria: Patients with ...

7. Oncology (Medical) - Doctors - Mayo Clinic

   ... coagulation, Bleeding disorder, Benign hematologic condition, Autoimmune hemolytic anemia, Paroxysmal nocturnal hemoglobinuria, Myeloproliferative disorders ...

8. News Release

   Have had a difficult time with previous colonoscopy procedures. • Are on anti-coagulant drugs. • Have a colon obstruction. • Prefer not to have a standard ...

9. Oncology (Medical) - Doctors - Mayo Clinic

   ... coagulation, Bleeding disorder, Benign hematologic condition, Autoimmune hemolytic anemia, Paroxysmal nocturnal hemoglobinuria, Myeloproliferative disorders ...

10. PAC203: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL) (PACIFICA) - Mayo Clinic

    Adequate coagulation function, defined by prothrombin time (PT)/international normalized ratio (INR), international normalized ration (INR) and partial ...